nach oben

Erschienen in:

03.09.2019 | Original Article

Performance of novel non-invasive urine assay UroSEEK in cohorts of equivocal urine cytology

verfasst von: Maria Del Carmen Rodriguez Pena, Simeon U. Springer, Diana Taheri, Lu Li, Aline C. Tregnago, Marie-Lisa Eich, Isam-Eldin A. Eltoum, Christopher J. VandenBussche, Nickolas Papadopoulos, Kenneth W. Kinzler, Bert Vogelstein, George J. Netto

Erschienen in: Virchows Archiv | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Urine cytology is an essential element of the diagnostic work up of hematuria. A significant proportion of cases continue to be placed in the “atypical” or “suspicious” categories of the Paris system for urine cytology, posing difficulty in patient management. We report on the performance of our recently described urine-based assay “UroSEEK” in cases with equivocal diagnosis in patients who are investigated for bladder cancer. Urine samples were collected from two cohorts. The first consisted of patients who presented with hematuria or lower urinary tract symptoms (early detection cohort) and the second of patients that are in follow-up for prior bladder cancer (surveillance cohort). Urine samples were analyzed for mutations in 11 genes and aneuploidy. In the early detection setting, we found high sensitivity and specificity (96% and 88%, respectively) and a strong negative predictive value of 99%. The assay performance was less robust in the surveillance cohort (sensitivity of 74%, specificity of 72%, and negative predictive value of 53%). UroSEEK demonstrated a notable lead time to cancer diagnosis. Seven cases in the early detection cohort and 71 surveillance cases were detected at least 6 months prior to clinical diagnosis. Our results suggest a potential role for UroSEEK assay in guiding management of patients with atypical urine cytology if confirmed in future prospective trials.

Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69:7–34. https://doi.org/10.3322/caac.21551CrossRefPubMed

Lotan Y, Roehrborn CG (2003) Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 61:109–118 discussion 118CrossRefPubMed

Sullivan PS, Chan JB, Levin MR, Rao J (2010) Urine cytology and adjunct markers for detection and surveillance of bladder cancer. Am J Transl Res 2:412–440PubMedPubMedCentral

Xie Q, Huang Z, Zhu Z, Zheng X, Liu J, Zhang M, Zhang Y (2016) Diagnostic value of urine cytology in bladder cancer. A meta-analysis. Anal Quant Cytopathol Histopathol 38:38–44

Barkan GA, Wojcik EM, Nayar R, Savic-Prince S, Quek ML, Kurtycz DF, Rosenthal DL (2016) The Paris system for reporting urinary cytology: the quest to develop a standardized terminology. Adv Anat Pathol 23:193–201. https://doi.org/10.1097/PAP.0000000000000118CrossRefPubMed

Piaton E, Decaussin-Petrucci M, Mege-Lechevallier F, Advenier AS, Devonec M, Ruffion A (2014) Diagnostic terminology for urinary cytology reports including the new subcategories ‘atypical urothelial cells of undetermined significance’ (AUC-US) and ‘cannot exclude high grade’ (AUC-H). Cytopathology 25:27–38. https://doi.org/10.1111/cyt.12050CrossRefPubMed

Rosenthal DL, Vandenbussche CJ, Burroughs FH, Sathiyamoorthy S, Guan H, Owens C (2013) The Johns Hopkins Hospital template for urologic cytology samples: part I-creating the template. Cancer Cytopathol 121:15–20. https://doi.org/10.1002/cncy.21255CrossRefPubMed

Netto GJ (2011) Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet? Nat Rev Urol 9:41–51. https://doi.org/10.1038/nrurol.2011.193CrossRefPubMed

Lopez-Knowles E, Hernandez S, Malats N, Kogevinas M, Lloreta J, Carrato A, Tardon A, Serra C, Real FX (2006) PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res 66:7401–7404. https://doi.org/10.1158/0008-5472.can-06-1182CrossRefPubMed

10.

Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC (2010) FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One 5:e13821. https://doi.org/10.1371/journal.pone.0013821CrossRefPubMedPubMedCentral

11.

Oxford G, Theodorescu D (2003) The role of Ras superfamily proteins in bladder cancer progression. J Urol 170:1987–1993. https://doi.org/10.1097/01.ju.0000088670.02905.78CrossRefPubMed

12.

Mitra AP, Datar RH, Cote RJ (2006) Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol Off J Am Soc Clin Oncol 24:5552–5564. https://doi.org/10.1200/jco.2006.08.2073CrossRef

13.

Wu XR (2005) Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 5:713–725. https://doi.org/10.1038/nrc1697CrossRefPubMed

14.

Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, Mandahl N, Meeker AK, Mertens F, Netto GJ, Rasheed BA, Riggins GJ, Rosenquist TA, Schiffman M, Shih Ie M, Theodorescu D, Torbenson MS, Velculescu VE, Wang TL, Wentzensen N, Wood LD, Zhang M, McLendon RE, Bigner DD, Kinzler KW, Vogelstein B, Papadopoulos N, Yan H (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 110:6021–6026. https://doi.org/10.1073/pnas.1303607110CrossRefPubMedPubMedCentral

15.

Scott GA, Laughlin TS, Rothberg PG (2014) Mutations of the TERT promoter are common in basal cell carcinoma and squamous cell carcinoma. Mod Pathol 27:516–523. https://doi.org/10.1038/modpathol.2013.167CrossRefPubMed

16.

Heidenreich B, Rachakonda PS, Hemminki K, Kumar R (2014) TERT promoter mutations in cancer development. Curr Opin Genet Dev 24:30–37. https://doi.org/10.1016/j.gde.2013.11.005CrossRefPubMed

17.

Kinde I, Munari E, Faraj SF, Hruban RH, Schoenberg M, Bivalacqua T, Allaf M, Springer S, Wang Y, Diaz LA Jr, Kinzler KW, Vogelstein B, Papadopoulos N, Netto GJ (2013) TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res 73:7162–7167. https://doi.org/10.1158/0008-5472.can-13-2498CrossRefPubMedPubMedCentral

18.

Rodriguez Pena MDC, Tregnago AC, Eich ML, Springer S, Wang Y, Taheri D, Ertoy D, Fujita K, Bezerra SM, Cunha IW, Raspollini MR, Yu L, Bivalacqua TJ, Papadopoulos N, Kinzler KW, Vogelstein B, Netto GJ (2017) Spectrum of genetic mutations in de novo PUNLMP of the urinary bladder. Virchows Arch 471:761–767. https://doi.org/10.1007/s00428-017-2164-5CrossRefPubMed

19.

Palsgrove DN, Taheri D, Springer SU, Cowan M, Guner G, Mendoza Rodriguez MA, Del Carmen Rodriguez Pena M, Wang Y, Kinde I, Ricardo BFP, Cunha I, Fujita K, Ertoy D, Kinzler KW, Bivalacqua TJ, Papadopoulos N, Vogelstein B, Netto GJ (2018) Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations. Hum Pathol. https://doi.org/10.1016/j.humpath.2018.10.033

20.

Cowan ML, Springer S, Nguyen D, Taheri D, Guner G, Mendoza Rodriguez MA, Wang Y, Kinde I, Del Carmen Rodriguez Pena M, CJ VB, Olson MT, Cunha I, Fujita K, Ertoy D, Kinzler K, Bivalacqua T, Papadopoulos N, Vogelstein B, Netto GJ (2016) Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder. Hum Pathol 53:8–13. https://doi.org/10.1016/j.humpath.2016.02.009CrossRefPubMedPubMedCentral

21.

Nguyen D, Taheri D, Springer S, Cowan M, Guner G, Mendoza Rodriguez MA, Wang Y, Kinde I, VandenBussche CJ, Olson MT, Ricardo BF, Cunha I, Fujita K, Ertoy D, Kinzler KW, Bivalacqua TJ, Papadopoulos N, Vogelstein B, Netto GJ (2016) High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma. Virchows Arch 469:427–434. https://doi.org/10.1007/s00428-016-2001-2CrossRefPubMedPubMedCentral

22.

Fradet Y, Lockhard C (1997) Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt trade mark. Can J Urol 4:400–405PubMed

23.

Kruger S, Mess F, Bohle A, Feller AC (2003) Numerical aberrations of chromosome 17 and the 9p21 locus are independent predictors of tumor recurrence in non-invasive transitional cell carcinoma of the urinary bladder. Int J Oncol 23:41–48PubMed

24.

Skacel M, Fahmy M, Brainard JA, Pettay JD, Biscotti CV, Liou LS, Procop GW, Jones JS, Ulchaker J, Zippe CD, Tubbs RR (2003) Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 169:2101–2105. https://doi.org/10.1097/01.ju.0000066842.45464.ccCrossRefPubMed

25.

Sarosdy MF, Kahn PR, Ziffer MD, Love WR, Barkin J, Abara EO, Jansz K, Bridge JA, Johansson SL, Persons DL, Gibson JS (2006) Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. J Urol 176:44–47. https://doi.org/10.1016/s0022-5347(06)00576-3CrossRefPubMed

26.

Serizawa RR, Ralfkiaer U, Steven K, Lam GW, Schmiedel S, Schuz J, Hansen AB, Horn T, Guldberg P (2011) Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events. Int J Cancer 129:78–87. https://doi.org/10.1002/ijc.25651CrossRefPubMed

27.

Kawauchi S, Sakai H, Ikemoto K, Eguchi S, Nakao M, Takihara H, Shimabukuro T, Furuya T, Oga A, Matsuyama H, Takahashi M, Sasaki K (2009) 9p21 index as estimated by dual-color fluorescence in situ hybridization is useful to predict urothelial carcinoma recurrence in bladder washing cytology. Hum Pathol 40:1783–1789. https://doi.org/10.1016/j.humpath.2009.06.011CrossRefPubMed

28.

Allory Y, Beukers W, Sagrera A, Flandez M, Marques M, Marquez M, van der Keur KA, Dyrskjot L, Lurkin I, Vermeij M, Carrato A, Lloreta J, Lorente JA, Carrillo-de Santa Pau E, Masius RG, Kogevinas M, Steyerberg EW, van Tilborg AA, Abas C, Orntoft TF, Zuiverloon TC, Malats N, Zwarthoff EC, Real FX (2014) Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol 65:360–366. https://doi.org/10.1016/j.eururo.2013.08.052CrossRefPubMed

29.

Bansal N, Gupta A, Sankhwar SN, Mahdi AA (2014) Low- and high-grade bladder cancer appraisal via serum-based proteomics approach. Clin Chim Acta 436:97–103. https://doi.org/10.1016/j.cca.2014.05.012CrossRefPubMed

30.

Hurst CD, Platt FM, Knowles MA (2014) Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine. Eur Urol 65:367–369. https://doi.org/10.1016/j.eururo.2013.08.057CrossRefPubMed

31.

Ralla B, Stephan C, Meller S, Dietrich D, Kristiansen G, Jung K (2014) Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies. Crit Rev Clin Lab Sci 51:200–231. https://doi.org/10.3109/10408363.2014.914888CrossRefPubMed

32.

Ellinger J, Muller SC, Dietrich D (2015) Epigenetic biomarkers in the blood of patients with urological malignancies. Expert Rev Mol Diagn 15:505–516. https://doi.org/10.1586/14737159.2015.1019477CrossRefPubMed

33.

Yafi FA, Brimo F, Steinberg J, Aprikian AG, Tanguay S, Kassouf W (2015) Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. Urol Oncol 33:66.e25–66.e31. https://doi.org/10.1016/j.urolonc.2014.06.008CrossRef

34.

Wang Z, Que H, Suo C, Han Z, Tao J, Huang Z, Ju X, Tan R, Gu M (2017) Evaluation of the NMP22 BladderChek test for detecting bladder cancer: a systematic review and meta-analysis. Oncotarget 8:100648–100656. https://doi.org/10.18632/oncotarget.22065CrossRefPubMedPubMedCentral

35.

Halling KC, Kipp BR (2008) Bladder cancer detection using FISH (UroVysion assay). Adv Anat Pathol 15:279–286. https://doi.org/10.1097/PAP.0b013e3181832320CrossRefPubMed

36.

Springer SU, Chen CH, Rodriguez Pena MDC, Li L, Douville C, Wang Y, Cohen JD, Taheri D, Silliman N, Schaefer J, Ptak J, Dobbyn L, Papoli M, Kinde I, Afsari B, Tregnago AC, Bezerra SM, VandenBussche C, Fujita K, Ertoy D, Cunha IW, Yu L, Bivalacqua TJ, Grollman AP, Diaz LA, Karchin R, Danilova L, Huang CY, Shun CT, Turesky RJ, Yun BH, Rosenquist TA, Pu YS, Hruban RH, Tomasetti C, Papadopoulos N, Kinzler KW, Vogelstein B, Dickman KG, Netto GJ (2018) Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. Elife 7. https://doi.org/10.7554/eLife.32143

37.

Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang ZF, Sheinfeld J, Fair WR, Herr HW, Reuter VE (1993) Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 85:53–59CrossRefPubMed

38.

Shackney SE, Berg G, Simon SR, Cohen J, Amina S, Pommersheim W, Yakulis R, Wang S, Uhl M, Smith CA et al (1995) Origins and clinical implications of aneuploidy in early bladder cancer. Cytometry 22:307–316. https://doi.org/10.1002/cyto.990220407CrossRefPubMed

39.

Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B (2011) Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A 108:9530–9535. https://doi.org/10.1073/pnas.1105422108CrossRefPubMedPubMedCentral

40.

Kinde I, Papadopoulos N, Kinzler KW, Vogelstein B (2012) FAST-SeqS: a simple and efficient method for the detection of aneuploidy by massively parallel sequencing. PLoS One 7:e41162. https://doi.org/10.1371/journal.pone.0041162CrossRefPubMedPubMedCentral

41.

Virk RK, Abro S, de Ubago JMM, Pambuccian SE, Quek ML, Wojcik EM, Mehrotra S, Chatt GU, Barkan GA (2017) The value of the UroVysion(R) FISH assay in the risk-stratification of patients with “atypical urothelial cells” in urinary cytology specimens. Diagn Cytopathol 45:481–500. https://doi.org/10.1002/dc.23686CrossRefPubMed

Titel: Performance of novel non-invasive urine assay UroSEEK in cohorts of equivocal urine cytology
verfasst von: Maria Del Carmen Rodriguez Pena
Simeon U. Springer
Diana Taheri
Lu Li
Aline C. Tregnago
Marie-Lisa Eich
Isam-Eldin A. Eltoum
Christopher J. VandenBussche
Nickolas Papadopoulos
Kenneth W. Kinzler
Bert Vogelstein
George J. Netto
Publikationsdatum: 03.09.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Virchows Archiv / Ausgabe 3/2020
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-019-02654-1

Springer Medizin

Performance of novel non-invasive urine assay UroSEEK in cohorts of equivocal urine cytology

Abstract

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Multi-institutional re-evaluation of prognostic factors in chromophobe renal cell carcinoma: proposal of a novel two-tiered grading scheme

Utility of FOS as diagnostic marker for osteoid osteoma and osteoblastoma

PAX8 expression in anaplastic thyroid carcinoma is less than those reported in early studies: a multi-institutional study of 182 cases using the monoclonal antibody MRQ-50

The subgross morphology of breast carcinomas: a single-institution series of 2033 consecutive cases documented in large-format histology slides

Salivary ghost cell carcinoma: case report and proposal of a new entity

Histological and molecular features of solitary fibrous tumor of the extremities: clinical correlation

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie